Calendario

<<  Maggio 2020  >>
 Lu  Ma  Me  Gi  Ve  Sa  Do 
      1  2  3
  4  5  6  7  8  910
11121314151617
18192021222324
25262728293031

In collaborazione con:

 

 

Eventi

Al momento non ci sono eventi disponibili.

Newsletter






HEALTHCARE UTILISATION AND COSTS ASSOCIATED WITH ADDING MONTELUKAST TO CURRENT THERAPY IN PATIENTS WITH MILD TO MODERATE ASTHMA AND CO-MORBID ALLERGIC RHINITIS: PRAACTICAL STUDY.

pharmacoeconomics.gifDal Negro, Roberto (1); Piskorz, Peter (2); Vives, Roberto (3); Guilera, Magda (4); Sazonov Kocevar, Vasilisa (5); Badia, Xavier (4)

(2) Pneumology Department, Outpatients Clinic, Wotomin, Poland
(3) Allergology Department, Hospital 12 Octubre, Madrid, Spain
(4) Health Outcomes Research Europe, Barcelona, Spain
(5) Outcomes Research, Merck & Co., Inc, Whitehouse Station, New Jersey, USA


ABSTRACT

Objective: To evaluate the healthcare resource use and costs associated with adding montelukast to therapy in patients with mild to moderate persistent asthma and co-morbid seasonal allergic rhinitis whose asthma is inadequately controlled by their current asthma therapy.

Leggi tutto...
 
COST-EFFECTIVENESS AND HEALTHCARE BUDGET IMPACT IN ITALY OF INHALED CORTICOSTEROIDS AND BROCHODILATORS FOR SEVERE AND VERY SEVERE COPD PATIENTS

polmoni.jpgRoberto Dal Negro1, M Eandi2, L Pradelli3, S Iannazzo3

1Lung Dept., Orlandi General Hospital, Bussolengo, Verona, Italy; 2Clinical Pharmacology, University of Torino, Italy; 3Advanced Research, Torino, Italy


Abstract:
Current practice guidelines for the treatment of COPD recommend the use of combined inhaled corticosteroids and long-acting bronchodilators in severe and very severe patients (GOLD stages III and IV). The aim of this study was to evaluate, through a simulation model, the economic consequences of this recommendation in Italy. We developed a cost-effectiveness analysis (CEA) on five alternative therapeutic strategies (salmeterol/fluticasone, SF; formoterol/budesonide, FB; salmeterol alone, S; fluticasone alone, F; control, C).

Leggi tutto...
 
RATES OF ASTHMA ATTACKS IN PATIENTS WITH PREVIOUSLY INADEQUATELY CONTROLLED MILD ASTHMA TREATED IN CLINICAL PRACTICE WITH COMBINATION DRUG THERAPY: AN EXPLORATORY POST-HOC ANALYSIS

 

bmc-pulmonary-medicine-b.jpg
Robert W Dal Negro (1), Luis Borderias (2), Qiaoyi Zhang (3), Tao Fan (*3), Vasilisa Sazonov (3), Magda Guilera (4) and Stephanie D Taylor (3)



Address: (1) Bussolengo Gen. Hospital, Verona, Italy, (2) San Jorge Hospital, Huesca, Spain, (3) Merck & Co, Inc., Whitehouse Station, NJ, USA and (4) HOREurope, Barcelona, Spain


Abstract

Background: Differences could exist in the likelihood of asthma attacks in patients treated with inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and montelukast (MON) (ICS/LABA/ MON) and patients treated with an inhaled corticosteroid (ICS) and montelukast (MON) (ICS/MON).

Allegati:
Scarica questo file (BMC_Pulmonary_Medicine.pdf)Scarica l'articolo originale195 Kb2 Downloads
Leggi tutto...
 
CULTURAL AND LINGUISTIC TESTING OF THE HANDLING QUESTIONNAIRE: A SPECIFIC INSTRUMENT FOR ASSESSING THE PATIENT’S ACCEPTABILITY OF DRY POWDER INHALERS.

copertinamonaldi.jpg* Roberto Walter Dal Negro
** Massimo Guerriero

* Head of Lung Dept., Orlandi Hospital, Bussolengo, Verona.
** E.S.I. Department, Statistics Section, University of Verona, Via Dell’Artigliere, 19 – 37129 Verona.

  

Summary

The testing and checking phases of a questionnaire are shortly described in the present paper, being  the identification of errors due to incorrect formulation of questions  the  main issues. The theoretical methods for “testing” a questionnaire has been examined in the first section, while the testing process for a specific questionnaire for assessing the patient’s acceptability of a dry powder device (the Handling Questionnaire) has been described in the second section, together with the grading of improvement achieved. 

Allegati:
Scarica questo file (pne69-4_04dalnegro_tech_rep.pdf)Scarica l'articolo originale80 Kb0 Downloads
Leggi tutto...
 
OPTIMIZING ECONOMIC OUTCOMES IN THE MANAGEMENT OF COPD

polmoni.jpgRoberto Dal Negro

Lung Dept., Orlandi General Hospital, Bussolengo, Verona Italy;


ABSTRACT

Attention to COPD is increasing worldwide because its high prevalence, morbidity, and mortality present a challenging problem for all healthcare systems. The burden of COPD, which is usually measured in terms of progressive lung function decline, impact on patients’ symptoms, patient’s disability, and quality of life, together with the corresponding use of health care resources, is still a major aspect of the disease.

Recommendations to treat COPD according to the most accepted guidelines have expanded in recent years even though COPD still remains unacceptably under-diagnosed and under-treated worldwide.

Leggi tutto...
 
EFFETTI DELLA OSSIGENOTERAPIA A LUNGO TERMINE (OTLT) SULLA MORTALITÀ DI SOGGETTI CON IRC

Paola Turco, MD, PhD

 

Nei pazienti affetti da malattie polmonari in stadio avanzato, gli effetti benefici dell’ossigenoterapia in corso di ipossiemia persistente rappresentano un dato consolidato fin dai tempi dell’introduzione dell’ossigeno come agente terapeutico. 

Leggi tutto...
 
« InizioPrec.1 »

Pagina 1 di 2